Key result
Iloprost was equipotent to PGI2 against ADP-induced platelet aggregation but more potent against adrenaline- and arachidonic acid-induced aggregation in human whole blood.
Why the study?
Does Iloprost inhibit platelet aggregation more effectively than Prostacyclin in human whole blood?
Population
Human whole blood (in vitro model)
Comparison
Iloprost (ZK36374) 1-6 nM vs Prostacyclin (PGI2) 1-6 nM
Design
Preclinical
Authors
Loading...
Should not yet change antiplatelet practice; leaves open whether potency differences translate in vivo.
Does Iloprost inhibit platelet aggregation more effectively than Prostacyclin in human whole blood?
Iloprost, a chemically stable prostacyclin analogue, is equipotent or more potent than prostacyclin in inhibiting platelet aggregation in human whole blood.
Saniabadi et al. (2009) studied this question. Iloprost (ZK36374) vs. Prostacyclin (PGI2) (1-6 nM) was evaluated on Inhibition of platelet aggregation induced by ADP, adrenaline, and arachidonic acid. Iloprost was equipotent to PGI2 against ADP-induced platelet aggregation but more potent against adrenaline- and arachidonic acid-induced aggregation in human whole blood.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: